Altmetrics
Downloads
113
Views
30
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
29 June 2023
Posted:
30 June 2023
You are already at the latest version
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
29 June 2023
Posted:
30 June 2023
You are already at the latest version
Number of patients (%) (n=70) |
|
---|---|
Age, mean ± SD | 69.6 ± 10.8 |
Gender | |
Male | 38 (54.3) |
Female | 32 (45.7) |
Body mass index, mean ± SD | 23.4 ± 3.5 |
ASA score | |
II | 35 (50.0) |
III | 35 (50.0) |
Medical history | |
None | 19 (27.1) |
One | 18 (25.7) |
Two or more | 33 (47.1) |
Tumor location | |
Right | 19 (27.1) |
Left | 27 (38.6) |
Rectum | 24 (34.3) |
CEA | |
<5 | 45 (64.3) |
≥5 | 25 (35.7) |
Operation method | |
Open | 15 (21.4) |
MIS | 55 (78.6) |
T stage | |
Tis | 1 (1.4) |
3 | 53 (75.7) |
4 | 16 (22.9) |
N stage | |
0 | 28 (40.0) |
1 | 28 (40.0) |
2 | 14 (20.0) |
M stage | |
0 | 57 (81.4) |
1 | 13 (18.6) |
TNM stage | |
0 | 1 (1.4) |
2 | 25 (35.7) |
3 | 31 (44.3) |
4 | 13 (18.6) |
Metastatic lymph node, mean ± SD | 2.2 ± 3.6 |
Harvested lymph node, mean ± SD | 24.8 ± 11.1 |
Tumor differentiation | |
Well differentiation | 13 (18.8) |
Moderate differentiation | 53 (76.8) |
Poorly differentiation | 1 (1.4) |
Mucinous adenocarcinoma | 2 (2.9) |
Tumor size (cm), mean ± SD | 5.0 ± 2.0 |
Lymphatic invasion | |
Negative | 38 (54.3) |
Positive | 32 (45.7) |
Venous invasion | |
Negative | 63 (90.0) |
Positive | 7 (10.0) |
Perineural invasion | |
Negative | 50 (71.4) |
Positive | 20 (28.6) |
EGFR | |
Negative | 5 (7.6) |
Positive | 61 (92.4) |
MSI | |
MSS | 63 (94.0) |
MSI-H | 4 (6.0) |
KRAS | |
Wild | 39 (58.2) |
Mutant | 28 (41.8) |
NRAS | |
Wild | 47 (92.2) |
Mutant | 2 (3.9) |
BRAF | |
Wild | 62 (95.4) |
Mutant | 3 (4.6) |
Laboratory markers, mean ± SD | |
WBC (103/μL) | 7.6 ± 3.1 |
Hb (g/dL) | 11.9 ± 2.4 |
PLT (103/μL) | 288.0 ± 100.3 |
Neutrophil count (103/μL) | 5.4 ± 3.0 |
Lymphocyte count (103/μL) | 1.5 ± 0.6 |
NLR | 4.5 ± 4.9 |
C-reactive protein (mg/dL) | 1.7 ± 2.7 |
Albumin (g/dL) | 3.8 ± 0.6 |
Chemotherapy | |
No | 24 (34.3) |
Yes | 46 (65.7) |
Radiotherapy | |
No | 69 (98.6) |
Yes | 1 (1.4) |
Recurrence | |
No | 42 (60.0) |
Yes | 17 (24.3) |
Death | |
No | 45 (64.3) |
Yes | 5 (7.1) |
Median [IQR] | Range | |
---|---|---|
APRIL/TNFSF13 | 166.02 [0, 806.4] | 0~8954.58 |
BAFF | 485.6 [355.3, 664.0] | 0~2053.2 |
CHIT | 21.3 [10.24, 31.24] | 0~101.19 |
MMP-3 | 905.1 [736.2, 1106.9] | 270.5~5198.8 |
Osteocalcin | 16.33 [2.37, 41.34] | 0~487.48 |
Pentraxin-3 | 8.98 [7.41, 12.19] | 3.23~57.43 |
sTNF-R1 | 6.67 [5.43, 7.87] | 2.28~36.20 |
sTNF-R2 | 60.99 [35.78, 106.93] | 0~177.87 |
LAG-3 | 0 [0, 11.46] | 0~164.96 |
PD-1 | 5.3 [5.30, 10.84] | 0~21.77 |
PD-L1 | 0 [0, 0.43] | 0~4.49 |
CTLA-4 | 0 [0, 0] | 0~3.1 |
APRIL/TNFSF13 (806.4) | BAFF (664.0) | MMP-3 (736.2) | |||||||
---|---|---|---|---|---|---|---|---|---|
Low (N=51) | High (N=19) | p | Low (N=52) | High (N=18) | p | Low (N=23) | High (N=47) | p | |
Age, mean ± SD | 69.8 ± 10.7 | 69.2 ± 11.0 | 0.82 | 69.4 ± 11.1 | 70.3 ± 10.1 | 0.74 | 70.7 ± 11.4 | 69.1 ± 10.5 | 0.59 |
Gender | |||||||||
Male | 27 (52.9) | 11 (57.9) | 0.92 | 25 (48.1) | 13 (72.2) | 0.13 | 15 (65.2) | 23 (48.9) | 0.30 |
Female | 24 (47.1) | 8 (42.1) | 27 (51.9) | 5 (27.8) | 8 (34.8) | 24 (51.1) | |||
BMI | 23.5 ± 3.7 | 23.1 ± 3.1 | 0.70 | 23.4 ± 3.7 | 23.4 ± 3.0 | 0.96 | 23.3 ± 3.6 | 23.4 ± 3.5 | 0.90 |
ASA score | |||||||||
II | 28 (54.9) | 7 (36.8) | 0.28 | 29 (55.8) | 6 (33.3) | 0.17 | 13 (56.5) | 22 (46.8) | 0.61 |
III | 23 (45.1) | 12 (63.2) | 23 (44.2) | 12 (66.7) | 10 (43.5) | 25 (53.2) | |||
Medical history | |||||||||
None | 14 (27.5) | 5 (26.3) | 0.95* | 12 (23.1) | 7 (38.9) | 0.22* | 6 (26.1) | 13 (27.7) | 0.81 |
One | 14 (27.5) | 4 (21.1) | 16 (30.8) | 2 (11.1) | 5 (21.7) | 13 (27.7) | |||
T or more | 23 (45.1) | 10 (52.6) | 24 (46.2) | 9 (50.0) | 12 (52.2) | 21 (44.7) | |||
Tumor location | |||||||||
Right | 15 (29.4) | 4 (21.1) | 0.65 | 17 (32.7) | 2 (11.1) | 0.13* | 8 (34.8) | 11 (23.4) | 0.51 |
Left | 20 (39.2) | 7 (36.8) | 20 (38.5) | 7 (38.9) | 7 (30.4) | 20 (42.6) | |||
Rectum | 16 (31.4) | 8 (42.1) | 15 (28.8) | 9 (50.0) | 8 (34.8) | 16 (34.0) | |||
CEA | |||||||||
<5 | 34 (66.7) | 11 (57.9) | 0.68 | 34 (65.4) | 11 (61.1) | 0.96 | 19 (82.6) | 26 (55.3) | 0.04 |
≥5 | 17 (33.3) | 8 (42.1) | 18 (34.6) | 7 (38.9) | 4 (17.4) | 21 (44.7) | |||
Operation method | |||||||||
Open | 10 (19.6) | 5 (26.3) | 0.53* | 11 (21.2) | 4 (22.2) | 1* | 6 (26.1) | 9 (19.1) | 0.54* |
MIS | 41 (80.4) | 14 (73.7) | 41 (78.8) | 14 (77.8) | 17 (73.9) | 38 (80.9) | |||
T stage | |||||||||
Tis | 0 (0.0) | 1 (5.3) | 0.29* | 0 (0.0) | 1 (5.6) | 0.09* | 0 (0.0) | 1 (2.1) | 0.01* |
3 | 40 (78.4) | 13 (68.4) | 42 (80.8) | 11 (61.1) | 22 (95.7) | 31 (66.0) | |||
4 | 11 (21.6) | 5 (26.3) | 10 (19.2) | 6 (33.3) | 1 (4.3) | 15 (31.9) | |||
N stage | |||||||||
0 | 22 (43.1) | 6 (31.6) | 0.60* | 20 (38.5) | 8 (44.4) | 0.81* | 13 (56.5) | 15 (31.9) | 0.15* |
1 | 20 (39.2) | 8 (42.1) | 22 (42.3) | 6 (33.3) | 6 (26.1) | 22 (46.8) | |||
2 | 9 (17.6) | 5 (26.3) | 10 (19.2) | 4 (22.2) | 4 (17.4) | 10 (21.3) | |||
M stage | |||||||||
0 | 45 (88.2) | 12 (63.2) | 0.03* | 45 (86.5) | 12 (66.7) | 0.08* | 21 (91.3) | 36 (76.6) | 0.19* |
1 | 6 (11.8) | 7 (36.8) | 7 (13.5) | 6 (33.3) | 2 (8.7) | 11 (23.4) | |||
TNM stage | |||||||||
0 | 0 (0.0) | 1 (5.3) | 0.02* | 0 (0.0) | 1 (5.6) | 0.06* | 0 (0.0) | 1 (2.1) | 0.04* |
2 | 21 (41.2) | 4 (21.1) | 19 (36.5) | 6 (33.3) | 13 (56.5) | 12 (25.5) | |||
3 | 24 (47.1) | 7 (36.8) | 26 (50.0) | 5 (27.8) | 8 (34.8) | 23 (48.9) | |||
4 | 6 (11.8) | 7 (36.8) | 7 (13.5) | 6 (33.3) | 2 (8.7) | 11 (23.4) | |||
Metastatic lymph node | 1.8 ± 3.3 | 3.2 ± 4.3 | 0.23 | 2.0 ± 3.3 | 2.8 ± 4.4 | 0.45 | 1.1 ± 1.7 | 2.7 ± 4.2 | 0.02 |
Harvested lymph node | 24.4 ± 9.4 | 25.9 ± 14.9 | 0.68 | 25.3 ± 9.8 | 23.4 ± 14.4 | 0.62 | 27.1 ± 13.1 | 23.7 ± 9.9 | 0.27 |
Tumor differentiation | |||||||||
WD | 10 (19.6) | 3 (16.7) | 0.79* | 9 (17.3) | 4 (23.5) | 0.63* | 4 (17.4) | 9 (19.6) | 0.91* |
MD | 39 (76.5) | 14 (77.8) | 41 (78.8) | 12 (70.6) | 19 (82.6) | 34 (73.9) | |||
PD | 1 (2.0) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 1 (2.2) | |||
Mucinous | 1 (2.0) | 1 (5.6) | 1 (1.9) | 1 (5.9) | 0 (0.0) | 2 (4.3) | |||
Tumor size (cm), mean ± SD | 4.9 ± 2.2 | 5.2 ± 1.3 | 0.50 | 4.9 ± 2.2 | 5.1 ± 1.5 | 0.64 | 4.8 ± 2.0 | 5.0 ± 2.1 | 0.74 |
Lymphatic invasion | |||||||||
Negative | 28 (54.9) | 10 (52.6) | 1 | 28 (53.8) | 10 (55.6) | 1 | 11 (47.8) | 27 (57.4) | 0.61 |
Positive | 23 (45.1) | 9 (47.4) | 24 (46.2) | 8 (44.4) | 12 (52.2) | 20 (42.6) | |||
Venous invasion | |||||||||
Negative | 47 (92.2) | 16 (84.2) | 0.37* | 47 (90.4) | 16 (88.9) | 1* | 21 (91.3) | 42 (89.4) | 1* |
Positive | 4 (7.8) | 3 (15.8) | 5 (9.6) | 2 (11.1) | 2 (8.7) | 5 (10.6) | |||
Perineural invasion | |||||||||
Negative | 40 (78.4) | 10 (52.6) | 0.06 | 40 (76.9) | 10 (55.6) | 0.15 | 19 (82.6) | 31 (66.0) | 0.24 |
Positive | 11 (21.6) | 9 (47.4) | 12 (23.1) | 8 (44.4) | 4 (17.4) | 16 (34.0) | |||
EGFR | |||||||||
Negative | 1 (2.1) | 4 (22.2) | 0.01* | 1 (2.0) | 4 (25.0) | 0.01* | 0 (0.0) | 5 (11.6) | 0.15* |
Positive | 47 (97.9) | 14 (77.8) | 49 (98.0) | 12 (75.0) | 23 (100.0) | 38 (88.4) | |||
MSI | |||||||||
MSS | 46 (92.0) | 17 (100.0) | 0.56* | 47 (92.2) | 16 (100.0) | 0.56* | 21 (91.3) | 42 (95.5) | 0.60* |
MSI-H | 4 (8.0) | 0 (0.0) | 4 (7.8) | 0 (0.0) | 2 (8.7) | 2 (4.5) | |||
KRAS | |||||||||
Wild | 27 (56.2) | 12 (63.2) | 0.80 | 29 (59.2) | 10 (55.6) | 1 | 12 (57.1) | 27 (58.7) | 1 |
Mutant | 21 (43.8) | 7 (36.8) | 20 (40.8) | 8 (44.4) | 9 (42.9) | 19 (41.3) | |||
NRAS | |||||||||
Wild | 33 (97.1) | 14 (93.3) | 0.52* | 35 (97.2) | 12 (92.3) | 0.46* | 16 (100.0) | 31 (93.9) | 1* |
Mutant | 1 (2.9) | 1 (6.7) | 1 (2.8) | 1 (7.7) | 0 (0.0) | 2 (6.1) | |||
BRAF | |||||||||
Wild | 45 (95.7) | 17 (94.4) | 1* | 45 (93.8) | 17 (100.0) | 0.56* | 19 (95.0) | 43 (95.6) | 1* |
Mutant | 2 (4.3) | 1 (5.6) | 3 (6.2) | 0 (0.0) | 1 (5.0) | 2 (4.4) | |||
Laboratory markers, median [IQR] | |||||||||
WBC (103/μL) | 6.6 [5.4, 9.2] | 7.1 [6.5, 8.8] | 0.53 | 7.2 [5.5, 9.2] | 6.7 [5.9, 8.9] | 0.83 | 6.5 [4.9, 7.6] | 7.2 [5.9, 9.4] | 0.10 |
Hb (g/dL) | 12.6 [10.4, 13.6] | 11.1 [9.7, 12.5] | 0.13 | 12.4 [10.2, 13.4] | 12.4 [9.8, 13.8] | 0.87 | 12.4 [10.1, 13.8] | 12.3 [10.2, 13.6] | 0.58 |
PLT (103/μL) | 272.0 [209.5, 323.0] | 253.0 [231.0, 331.0] | 0.92 | 275.5 [212.2, 333.5] | 242.0 [224.5, 294.2] | 0.37 | 260.0 [193.0, 307.0] | 259.0 [222.5, 332.5] | 0.42 |
Neutrophil (103/μL) | 4.7 [3.0, 6.4] | 5.1 [4.4, 7.1] | 0.17 | 4.7 [3.1, 6.9] | 4.9 [4.3, 6.8] | 0.38 | 3.6 [3.0, 5.8] | 4.9 [3.7, 7.1] | 0.08 |
Lymphocyte (103/μL) | 1.6 [1.3, 1.9] | 1.3 [1.0, 1.8] | 0.20 | 1.5 [1.2, 1.9] | 1.3 [1.0, 1.8] | 0.49 | 1.4 [1.2, 1.7] | 1.6 [1.1, 1.9] | 0.48 |
NLR | 2.7 [2.1, 4.2] | 4.1 [2.7, 6.0] | 0.04 | 2.7 [2.2, 4.4] | 3.9 [2.7, 5.4] | 0.15 | 2.5 [2.1, 4.1] | 3.6 [2.5, 5.2] | 0.16 |
CRP (mg/dL) | 0.4 [0.3, 1.6] | 1.0 [0.3, 2.3] | 0.25 | 0.5 [0.3, 1.8] | 0.7 [0.3, 1.3] | 0.97 | 0.6 [0.3, 1.3] | 0.7 [0.3, 1.8] | 0.99 |
Albumin (g/dL) | 3.9 [3.6, 4.3] | 3.7 [3.2, 4.0] | 0.07 | 3.9 [3.6, 4.2] | 3.8 [3.3, 4.2] | 0.58 | 3.8 [3.2, 4.2] | 3.9 [3.5, 4.3] | 0.31 |
Chemotherapy | |||||||||
No | 17 (33.3) | 7 (36.8) | 1 | 16 (30.8) | 8 (44.4) | 0.44 | 9 (39.1) | 15 (31.9) | 0.74 |
Yes | 34 (66.7) | 12 (63.2) | 36 (69.2) | 10 (55.6) | 14 (60.9) | 32 (68.1) | |||
Radiotherapy | |||||||||
No | 50 (98.0) | 19 (100.0) | 1* | 51 (98.1) | 18 (100.0) | 1* | 22 (95.7) | 47 (100.0) | 0.32* |
Yes | 1 (2.0) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 1 (4.3) | 0 (0.0) | |||
Recurrence | |||||||||
No | 34 (66.7) | 8 (42.1) | 0.06* | 35 (67.3) | 7 (38.9) | 0.03* | 16 (69.6) | 26 (55.3) | 0.08* |
Yes | 12 (23.5) | 5 (26.3) | 12 (23.1) | 5 (27.8) | 2 (8.7) | 15 (31.9) | |||
Death | |||||||||
No | 36 (70.6) | 9 (47.4) | 0.11* | 37 (71.2) | 8 (44.4) | 0.08* | 16 (69.6) | 29 (61.7) | 0.78* |
Yes | 4 (7.8) | 1 (5.3) | 3 (5.8) | 2 (11.1) | 1 (4.3) | 4 (8.5) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated